Cannabis-Derived Ingredients in Cosmetic Products
Cannabis-derived ingredients are popular compounds with interesting properties. There is specific EU and national legislation regarding cannabis-derived ingredients, identifying which extracts and derivatives may be used in cosmetic products. There are several aspects to consider to ensure compliance when adding these compounds to cosmetics and personal care products.


Cannabidiol (CBD) is one of many different cannabinoids found and extracted from hemp (Cannabis sativa or Cannabis indica). Cannabidiol is normally located in the aerial parts of the plants (flowers, stems and leaves) and not in the roots or seeds. Although CBD is chemically similar to Tetrahydrocannabinol (THC), Cannabidiol does not cause a psychoactive effect (e.g. euphoric effects). Cannabigerol (CBG), another cannabinoid extracted from the plant, is a precursor molecule that can converted into other cannabinoids (like THC and CBD) during plant growth and is gaining more and more attention by consumers and the cosmetic industry.


In the European Union (EU) Cannabis sativa plant can be legally cultivated and supplied for industrial uses if the THC levels present in the plant do not surpass 0.2%.

According to Cosmetics Regulation (EC) No 1223/2009, there are several Cannabis-derivatives included in the list of substances prohibited in cosmetic products (Annex II) such as Cannabis and Cannabis resin (Cannabis sativa, ext.), Cannabis sativa flower extract, Cannabis sativa flower/stem extract or Cannabis sativa flower/leaf/stem extract. These substances cannot be used in cosmetic products under any circumstances. However, substances extracted from the seeds of Cannabis sativa, like Cannabis sativa seed oil and Cannabis sativa seed extract, among others, are allowed for use in cosmetic products if the THC level does not exceed 0.2% (THC is also included in Annex II).

Cannabidiol (CBD) is also included in the list of substances prohibited in cosmetic products (Annex II of the European Cosmetic Regulation). Its annex entry states that “Cannabidiol (CBD) as such, irrespective of its source, is not listed in the Schedules of the 1961 UN Single Convention on Narcotic Drugs. However, it shall be prohibited from use in cosmetic products (II/306) if it is prepared as an extract or tincture or resin of Cannabis in accordance with the Single Convention. Please note that national legislations on controlled substances may also apply.”.

This means that Cannabidiol may not be extracted from the flowers, fruits or resin because these parts have higher concentrations of THC. It can neither be prepared as an extract, tincture or resin. Cannabis seeds (when not accompanied with the fruiting tops) are not included in the list of banned ingredients of the Single Convention, so the use of Cannabidiol derived from seeds is not prohibited (again, THC levels cannot exceed 0.2%). Since CBD is mainly found in the aerial parts of the plants, the safest and most efficient way to legally use this substance in cosmetic products is by synthetic production.

Member States may have different regulations regarding Cannabis and its derivatives, which influence its use on cosmetic products. For example, France and Sweden have different restrictions for derivatives of Cannabis and its use on cosmetic products. On the other hand, Switzerland allows a maximum THC content of up to 1%.


In the United States, the 2018 Farm Bill (Agriculture Improvement Act of 2018, Pub. L., 115-334) excluded Cannabis and cannabis-derived compounds with a THC concentration of no more than 0.3% (dry weight basis) from the Controlled Substances Act (CSA), which means that these compounds are no longer controlled substances under federal law. The U.S. Food and Drug Administration (FDA) is the authority that regulates products containing Cannabis and its derivatives. In the U.S., Cannabis and its derivatives (defined as hemp – Farm Bill 2018) are not cosmetic ingredients prohibited or restricted by regulation. Nevertheless, it must be taken into account that “a product is intended to affect the structure or function of the body, or diagnose, cure, mitigate, treat or prevent disease, it is a drug, or possibly both a cosmetic and a drug, even if it affects the appearance” in accordance with FDA regulations.

If a manufacturer would like to have Cannabidiol on its formulation and commercialize the product in the European Union, they should use Cannabidiol which is 100% chemically produced. Moreover, manufacturers must take into account the country of origin of the Cannabis-derived ingredients used and also the tolerance for THC content that has been set out at national level for industrial hemp.

In cosmetics, the Responsible Person plays a determinant role safeguarding the compliance of Cannabidiol-containing cosmetic products with regulations and closely monitoring its commercialization across the European Union. These products must not claim having therapeutic effects and should not confuse the public about its cannabis content.

If you need to place your CBD containing products in the EU market and need further information or guidance on this matter, feel free to contact us at


  1. Single Convention on Narcotic Drugs, 1961. Available from:
  2. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). Available from:


news & updates

EU Ecolabel adoption and recognition are on the rise

The Ecolabel certification is a comprehensive program focused on fostering sustainable practices. It evaluates products based on life cycle assessments, where every phase of said life cycle must abide by strict standards to attain the Ecolabel certification. The overarching objective of this certification is minimizing environmental harm from production or consumption activities.

Read More »
news & updates

SCCS preliminary opinion on Citral sensitization endpoint

Ingredients: CITRAL

Date of publication: 27/03/2024

On March 27 2024, the Scientific Committee on Consumer Safety (SCCS) published the Preliminary Opinion on the safety of Citral in cosmetic products. The deadline for comments is set to June 2, 2024.

Read More »
cosmetic products

UK proposes ban of wet wipes containing plastic 

The UK has proposed, on April 24, 2024, a regulation titled The Environmental Protection (Wet Wipes Containing Plastic) (England) Regulations 2024, to the World Trade Organization (WTO). The regulation aims to eliminate the supply and sale of plastic-containing wet wipes, including cosmetic ones. The public can offer comments on the draft until June 23, 2024, with adoption expected in September of the same year.

Read More »
medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »